This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Dr Watts demonstrated that in healthy, normolipidemic subjects, evolocumab (420 mg every 2 weeks) decreased the concentration of atherogenic lipoproteins, particularly low-density lipoprotein (LDL), by accelerating their catabolism. Reductions in intermediate-density lipoprotein and LDL production also contributed to the decrease in LDL particle concentration with evolocumab by a mechanism distinct from that of atorvastatin (80 mg daily). These kinetic findings provide a metabolic basis for understanding the potential benefits of PCSK9 (proprotein convertase subtilisin/kexin type 9) monoclonal antibodies incremental to statins in on-going clinical end point trials.1
The first large trial to assess cardiovascular outcomes with a PCSK9 inhibitor reported that evolocumab treatment significantly reduced the risk of …
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
This Issue
Article Tools
Share this Article
- Letter by Koh Regarding Article, “Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism”Permalink:
